



Clinician	Number of patients referred
Jared Mathai	64
Tom Johns	41
Melinda Johns	32
Nick Pavlakis	29
Chee Lee	23
Sarah Heyermann	23
Ben Solomon	20
Máiréadha Kavanagh	20
Rebecca Tay	20
Sagan Parakh	17
Steven Kao	16
Veressa Chin	15
Adithya Balasubramanian	14
Praveena Bloman	14
Pei Ding	14
Jose Leal-Fernandez	14
Brett Hughes	13
Ben Markman	13
Zarnia Lwin	12
Geoffrey Peters	12
Melissa Moore	11
Richard Eas	11
Christopher Lomma	11
Shu Fen Wong	11
Linda Ye	11
Robert Zielinski	10

Table 1: Clinicians with ≥10 patients enrolled in ASPIRATION  
ASPIRATION 1000 patient cohort summary

# Australian Precision Oncology Symposium (APOS) 2025



Omico

Cancer  
meets its match



# Australian Precision Oncology Symposium 2025

- After the first 3,383 enrolled:
- > 60% of patients have had a matched treatment identified
  - Of these, 37.5% have a drug target (T1-3) which appears to be in a doubling of survival, if the drug is accessible.




## The Coming of Age of Precision Oncology


### We warmly invite you to exclusively attend the Australian Precision Oncology Symposium 2025!

APOS 25 Theme: The Coming of Age of Precision Oncology.

APOS 25 will showcase a pivotal moment in cancer care, as precision oncology moves from theory to transformative practice. Designed for Australian oncology professionals—including oncologists, researchers, pathologists, and members of the life science and advocacy sectors—APOS 25 is set to be an impactful gathering of thought leaders in precision oncology.



**Date:** Friday 7 – Saturday 8 March 2025



**Mode:** Face to Face & Online



**Location:**  
**Venue** – John Niland Scientia Building, UNSW Kensington campus Kensington, NSW, 2052  
**Address** – G19 Library Road, Kensington

### Key Dates

Registrations Close – Friday, 1 March 2025

### What to expect at APOS 25?

The symposium will bring together renowned international and local speakers, providing a rich spectrum of perspectives on the latest advancements in precision oncology. Attendees will engage with experts, explore groundbreaking research, and foster meaningful professional connections.

### Program highlights include:

- Cutting Edge Therapeutics: Updates on clinical trials of emerging important precision therapies.
- Technology Advances: Topics include blood-based multi-cancer early detection tests, homologous recombination deficiency, screening for antibody drug conjugates, synthetic lethality, and more.
- Real World Data Insights: Focused on long-term care and survivorship in the AYA (adolescent and young adult) space, quality of life in precision oncology settings, and emerging trends in proteomics.

- Clinical Impact: Discover what's on the pharmaco-genomics horizon relevant to management of cancer patients.
- Live Molecular Oncology Board: A unique, interactive session providing for real-time insights on translating precision oncology from theory to real-world application.

**For those attending in person,** this Symposium offers a unique networking opportunity, fostering collaboration and interaction among participants. Attendees will have the chance to connect with experts in the field, share insights, and build valuable professional relationships, enhancing the overall experience and impact of the event.

**For virtual participants,** you have the flexibility to access any or all of the five sessions in the program, tailoring your experience to focus on the topics most pertinent to your specific areas of interest.

# APOS 25 Speaker Faculty.

APOS 25 promises to present an exciting array of speakers, featuring two renowned international experts who will bring their global insights to the event.



**Professor Mark Middleton, UK**

*Head of the Department of Oncology, University of Oxford, UK*

Mark is Co-Director of Oxford Cancer and Head of Oncology at the University of Oxford, where he founded the Early Phase Clinical Trials Unit. His clinical and research interests are in new drug development, the treatment of upper GI tumours and the early detection of new and relapsing cancers.

He has been Chief or Principal Investigator on >100 trials and closely involved in the development of new therapies including DNA repair, immune checkpoint and kinase inhibitors, ImmTACs and oncolytic viruses. Mark trained in Medicine at the Universities of Cambridge and Oxford, and in Oncology at the Christie Hospital and University of Manchester.



**Dr Raoul Reulen PhD, UK**

*Associate Professor, Cancer Epidemiology, University of Birmingham, UK*

Raoul specialises in the long-term health risks faced by childhood, adolescent, and young adult cancer survivors. His research focuses on the British Childhood Cancer Survivor Study (BCCSS) and the Teenage and Young Adult Cancer Survivor Study (TYACSS), large-scale cohorts tracking health outcomes in over 235,000 survivors.

These studies provide key insights into late mortality, secondary cancers, cardiovascular disease, and other long-term effects of cancer treatment. Internationally, Raoul has contributed to major collaborative studies, including the EU-funded PanCareSurFup project, which examined cancer risks across 12 European countries.

In addition, a carefully curated selection of respected Australian professionals will also contribute to the program.



Professor David Thomas



A/Prof Oliver Klein



Dr Timothy Humphries



Dr Min Li Huang



Dr Sam Harris



Dr Malaka Ameratung



Dr Subo Thavaneswaran



A/Prof Anna Brown



Dr Maya Kansara



Professor Hilda Pickett



Dr Milita Zaheed



A/Prof Kathy Tucker



Professor Damien Kee



Professor Hui Gan



A/Prof Catherine Mitchell



Dr Noemi Fuentes-Bolanos




Dr Ronald Chan



Dr John Grady



Dr Amy Body



Dr Greg Gaughran



Dr Kosar Hooshmand

# APOS 25 Sponsors.



We would like to express our gratitude to our dedicated sponsors for their generous support of APOS 25.

Their contributions will play a pivotal role in making this event a success. We are proud to showcase our sponsors as part of this event and look forward to continuing our collaboration in the future.



## Silver Sponsors:



## Bronze Sponsors:



# APOS 25 Program.

Friday, 7 March 2025

## Session 1: Molecular therapeutics – Chaired by Dr Greg Gaughran

- |               |   |
|---------------|---|
| 1:00 – 1:10pm | <b>Welcome and opening remarks</b>  |
| 1:10 – 1:45pm | <b>MoST CIRCUIT – Immunotherapy succeeds in rare cancers</b><br>Associate Professor Oliver Klein – 25min talk, 10min Q&A  |
| 1:45 – 2:05pm | <b>Results from the phase 1 part of the PYNACLE study assessing Rezatapopt in patients with advanced solid tumors harboring a TP53 Y220C mutation</b><br>Dr Amy Body – 15min talk, 5min Q&A                           |
| 2:05 – 2:25pm | <b>Clinical results from a phase 1 trial of PRT3789, a first-in-class intravenous SMARCA2 degrader, in patients with advanced solid tumors with a SMARCA4 mutation</b><br>Dr Timothy Humphries – 15min talk, 5min Q&A |
| 2:25 – 2:35pm | <b>MAT2A inhibitor trial in progress</b><br>Dr Malaka Ameratunga – 7min talk, 3min Q&A  |
| 2:35 – 2:45pm | <b>Prevalence of MTAP deletion in Australia</b><br>Dr Sam Harris – 7min talk, 3min Q&A  |

## Session 2: Transforming technologies – Chaired by Prof. David Thomas

- |               |  |
|---------------|--|
| 3:15 – 3:50pm | <b>Precision diagnostics: Multi-cancer early detection using ctDNA in the SYMPLIFY study</b><br>Professor Mark Middleton – 25min talk, 10min Q&A   |
| 3:50 – 4:10pm | <b>Beyond Ovarian Cancer: Navigating the Challenges of Expanding HRD Testing</b><br>Associate Professor Anna Brown – 15min talk, 5min Q&A  |
| 4:10 – 4:30pm | <b>Omico's Screening Strategy for ADC/bispecific Ab Targets</b><br>Dr Maya Kansara – 15min talk, 5min Q&A  |
| 4:30 – 4:50pm | <b>Targeting telomere replication stress to treat ALT cancers</b><br>Professor Hilda Pickett – 15min talk, 5min Q&A  |
| 4:50 – 5:20pm | <b>Panel: Emerging technologies in precision oncology – Chaired by Prof. David Thomas</b><br>Prof Mark Middleton, A/Prof Anna Brown, Prof Hilda Pickett, Dr Maya Kansara – 30 min talk & Q&A |

Saturday, 8 March 2025

## Session 3: Cancer in the young and survivorship – Chaired by A/Prof. Mandy Ballinger

- |                 |   |
|-----------------|---|
| 9:00 – 9:10am   | <b>Opening remarks</b>  |
| 9:10 – 9:45am   | <b>Long-term adverse health outcomes in survivors of adolescent and young adult cancer</b><br>Dr Raoul Reulen – 25min talk, 10min Q&A                                     |
| 9:45 – 10:05am  | <b>Novel omics strategies for personalised risk management</b><br>Professor David Thomas – 15min talk, 5min Q&A   |
| 10:05 – 10:25am | <b>Germline cancer predisposition in the young</b><br>Dr Milita Zaheed – 15min talk, 5min Q&A   |
| 10:25 – 10:45am | <b>Panel: The changing face of germline cancer genetics</b><br>Professor David Thomas, Dr Milita Zaheed, A/Prof Kathy Tucker, Dr Noemi Fuentes-Bolanos – 20min talk & Q&A |

## Session 4: From research to clinical impact – Chaired by Dr Min Li Huang

- |                 |  |
|-----------------|--|
| 11:10 – 11:40am | <b>The evolving role of comprehensive genomic profiling in tumour diagnosis and classification.</b><br>A/Prof Catherine Mitchell – 20min talk, 10min Q&A                         |
| 11:40 – 12:00pm | <b>Detecting what's missing: Sensitivity trade-offs in liquid biopsies versus prior NGS panels and comparator CGP tissue biopsies</b><br>Dr Greg Gaughran – 15min talk, 5min Q&A |
| 12:00 – 12:20pm | <b>Pharmacogenetics and public health impact</b><br>Dr Kosar Hooshmand – 15min talk, 5min Q&A  |
| 12:20 – 12:40pm | <b>Impact of matched treatment – looking beyond survival</b><br>Dr Ronald Chan – 15min talk, 5min Q&A  |

## Session 5: Live molecular oncology board – Chaired by Prof. David Thomas

- |               |  |
|---------------|--|
| 1:30 – 2:30pm | <b>Individual cases from molecular pathology to treatment recommendations</b><br>Prof Hui Gan, Prof Damien Kee, Dr John Grady, Dr Min Li Huang, Dr Milita Zaheed, Dr Subo Thavaneswaran – 60min talk & Q&A |
| 2:30 – 2:45pm | <b>Close</b><br>Professor David Thomas   |



## Contact.

Should you have any questions or require further information, please contact:

Fidan Rasimoglou - Marketing Manager, Omico  
Email: [f.rasimoglou@omico.org.au](mailto:f.rasimoglou@omico.org.au)

[Omico.com.au](http://Omico.com.au)

Follow us @OmicoAustralia:

**f** **@** **in** **X**

©Copyright 2025. Australian Genomic Cancer Medicine Centre Ltd, trading as Omico, is a not for profit company limited by guarantee. Hilmer building (E10), Union Rd, UNSW, Kensington, NSW, 2052.